Loading…
Employees: 1,982
Size KYORIN Pharmaceutical (4569.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $362M, the 1243rd largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,084 on 6 Nov 2026.
Performance Over six months the shares fell 30.1%, against -20.8% for the median peer and +1.8% for the Japan market (cap-weighted) — 5th lowest of 19 in its peer set.
Growth Revenue fell 4.7% over the last twelve months (peer median +3.0%); the operating margin is 1.7% (peer median -16.3%).
Valuation It trades at 35.3× forward earnings against a peer median of 107.7× (3rd cheapest of 5).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.0 points below its cost of capital (5.0% WACC).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥126B | ¥126B | ¥130B | ¥120B | ¥113B |
| Revenue growth | — | -3% | +9% | +6% | — |
| Gross profit | ¥50.5B | ¥51.6B | ¥59.5B | ¥51.6B | ¥50.2B |
| EBITDA | ¥6.82B | ¥8.22B | ¥17.1B | ¥10.5B | ¥8.96B |
| Net income | ¥2.17B | ¥3.45B | ¥9.09B | ¥5.47B | ¥4.72B |
| Free cash flow | n/a | ¥2.52B | -¥2.19B | -¥4.23B | -¥4.32B |
| Capital expenditure | n/a | ¥3.98B | ¥6.29B | ¥6.25B | ¥9.40B |
| Total debt | ¥23.2B | ¥23.8B | ¥28.4B | ¥20.9B | ¥21.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4569.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.5% | -10.9% | 3rd highest of 20 |
| 6-month return | -30.1% | -20.8% | 5th lowest of 19 |
| Distance from 52-week high | -37.2% | -36.4% | 11th highest of 21 |
| Revenue growth (TTM) | -4.7% | +3.0% | 8th lowest of 19 |
| Operating margin | 1.7% | -16.3% | 6th highest of 17 |
| Forward P/E | 35.3× | 107.7× | 3rd cheapest of 5 |
| Growth the price implies (Req g, 7 yrs) | 10.5% | 9.0% | 3rd most demanding of 6 |
| Growth delivered (Del g) | +4.2% | +3.1% | 3rd highest of 6 |
| Hurdle (Req g minus delivered) | +6.3 pp | +6.8 pp | 3rd least demanding of 6 |
| ROIC minus cost of capital | -4.0 pp | -11.5 pp | 5th highest of 16 |
| EV / EBITDA | 9.3× | 15.4× | cheapest of 4 |
| Net debt / EBITDA | 0.9× | 0.4× | 2nd most indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 35.3× | 10.5% | +4.2% |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | n/a | n/a | n/a |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | n/a | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | n/a | 13.2% | +6.5% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | n/a | n/a | n/a |
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | n/a | 4.2% | +3.1% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | n/a | 16.3% | -14.0% |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 8.1× | -6.6% | +24.8% |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | n/a | n/a | n/a |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | n/a | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | n/a | 9.0% | -11.3% |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | n/a | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 295.1× | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | 12.3× | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 203.1× | n/a | n/a |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | n/a | n/a | n/a |